Positive high-level results from the primary analysis of the Phase III trial of AZD 1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis… read more.
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.
The Israel Ministry of Health (MoH), Pfizer Inc. and BioNTech SE announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the… read more.
The Medicines Health Regulatory Authority (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of Ixempra (ixabepilone) for the treatment of metastatic breast cancer.
Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada.
Melinta Therapeutics, LLC announced that the FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by… read more.
Johnson & Johnson welcomes the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson… read more.
Johnson & Johnson announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine JNJ 78436735, developed by the Janssen Pharmaceutical… read more.
Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19) and a related shot by the Serum Institute of India for use in Canada.
Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety… read more.
KemPharm, Inc. has announced that the FDA has approved the New Drug Application for Azstarys (formerly referred to as KP 415), a once-daily product for the treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
